← Leaderboards
Weiping Zou
University Of Michigan At Ann Arbor
$38,970,401
Attributed
$40,009,758
Total exposure
21
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,009,758 · 21
By mechanism
R01$36,227,211 · 16
T32$2,078,714 · 1
P30$1,155,183 · 3
R21$548,650 · 1
Top collaborators
- Jacqueline Sara Jeruss9 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Jindan Yu$10,147,010
- Steven Lynn Kunkel$20,708,735
- David J. Pinsky$32,329,328
- John K. Fink$5,422,389
- Jacques Eduardo Nor$18,171,241
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneMalignant NeoplasmsTumorT-LymphocytePhenotypeMolecularImmunotherapyCellsTumor ImmunityImmunityPathway InteractionsResponseMediatingImmune ResponseMalignant Neoplasm Of OvaryTumor MicroenvironmentRegulationBaseAffectInsightImmunotherapeutic AgentLinkClinical ResearchNovel Strategies
Grant awards (112)
Regulatory T cells in cancer therapy$647,392
R01 · FY2025 · CA · contact PI
CTL-killing capacity and cancer stiffness in cancer immunity and therapy$647,331
R01 · FY2025 · CA · contact PI
MS4A7 in tumor resistance to immunotherapy$630,650
R01 · FY2025 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$255,003
T32 · FY2025 · CA · contact PI
MS4A7 in tumor resistance to immunotherapy$651,124
R01 · FY2024 · CA · contact PI
Regulatory T cells in cancer therapy$614,963
R01 · FY2024 · CA · contact PI
CTL-killing capacity and cancer stiffness in cancer immunity and therapy$614,951
R01 · FY2024 · CA · contact PI
Metabolic impact on T cell-mediated cancer immunity and therapy$614,115
R01 · FY2024 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$257,366
T32 · FY2024 · CA · contact PI
Cancer Hematopoiesis and Immunology (CHI)$77,090
P30 · FY2024 · CA · contact PI
CTL-killing capacity and cancer stiffness in cancer immunity and therapy$634,364
R01 · FY2023 · CA · contact PI
Regulatory T cells in cancer therapy$634,296
R01 · FY2023 · CA · contact PI
Metabolic impact on T cell-mediated cancer immunity and therapy$633,444
R01 · FY2023 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$270,148
T32 · FY2023 · CA · contact PI
Cancer Hematopoiesis and Immunology (CHI)$78,771
P30 · FY2023 · CA · contact PI
CTL-killing capacity and cancer stiffness in cancer immunity and therapy$647,366
R01 · FY2022 · CA · contact PI
Regulatory T cells in cancer therapy$634,434
R01 · FY2022 · CA · contact PI
Metabolic impact on T cell-mediated cancer immunity and therapy$633,500
R01 · FY2022 · CA · contact PI
Ovarian Cancer Epigenetics, Immunity and Therapy$598,764
R01 · FY2022 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$253,930
T32 · FY2022 · CA · contact PI
Immunologic Monitoring (IM)$118,013
P30 · FY2022 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$67,505
P30 · FY2022 · CA · contact PI
Regulatory T cells in cancer therapy$647,349
R01 · FY2021 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$647,249
R01 · FY2021 · CA · contact PI
Metabolic impact on T cell-mediated cancer immunity and therapy$646,425
R01 · FY2021 · CA · contact PI
Ovarian Cancer Epigenetics, Immunity and Therapy$620,047
R01 · FY2021 · CA · contact PI
Immune Impact on Cancer Chemoresistance$613,838
R01 · FY2021 · CA · contact PI
Immunologic Monitoring (IM)$120,212
P30 · FY2021 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$81,011
R01 · FY2021 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$68,762
P30 · FY2021 · CA · contact PI
Metabolic impact on T cell-mediated cancer immunity and therapy$646,476
R01 · FY2020 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$642,318
R01 · FY2020 · CA · contact PI
Ovarian Cancer Epigenetics, Immunity and Therapy$621,601
R01 · FY2020 · CA · contact PI
Immune Impact on Cancer Chemoresistance$613,838
R01 · FY2020 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$220,328
T32 · FY2020 · CA · contact PI
Immunologic Monitoring (IM)$120,212
P30 · FY2020 · CA · contact PI
Naïve T Cells in Cancer Immune Evasion and Immunotherapy$81,011
R01 · FY2020 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$68,762
P30 · FY2020 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$614,741
R01 · FY2019 · CA · contact PI
Ovarian Cancer Epigenetics, Immunity and Therapy$602,952
R01 · FY2019 · CA · contact PI
Immune Impact on Cancer Chemoresistance$595,421
R01 · FY2019 · CA · contact PI
Effector T Cell Trafficking in Ovarian Cancer$498,552
R01 · FY2019 · CA · contact PI
MDSCs in Ovarian Cancer$483,308
R01 · FY2019 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$202,157
T32 · FY2019 · CA · contact PI
Immunologic Monitoring (IM)$120,214
P30 · FY2019 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$68,760
P30 · FY2019 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$625,446
R01 · FY2018 · CA · contact PI
Ovarian Cancer Epigenetics, Immunity and Therapy$621,601
R01 · FY2018 · CA · contact PI
Immune Impact on Cancer Chemoresistance$611,871
R01 · FY2018 · CA · contact PI
Effector T Cell Trafficking in Ovarian Cancer$513,972
R01 · FY2018 · CA · contact PI
MDSCs in Ovarian Cancer$498,257
R01 · FY2018 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$192,856
T32 · FY2018 · CA · contact PI
Immunologic Monitoring (IM)$120,148
P30 · FY2018 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$68,725
P30 · FY2018 · CA · contact PI
Immunologic Monitoring (IM)$9,970
P30 · FY2018 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$9,970
P30 · FY2018 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$8,972
P30 · FY2018 · CA · contact PI
Immunologic Monitoring (IM)$8,972
P30 · FY2018 · CA · contact PI
Immunologic Monitoring (IM)$7,663
P30 · FY2018 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$7,662
P30 · FY2018 · CA · contact PI
Immunologic Monitoring (IM)$2,401
P30 · FY2018 · CA · contact PI
Cancer Hematopoiesis & Immunology (CHI) Program$2,399
P30 · FY2018 · CA · contact PI
Naive T cells in Cancer Immune Evasion and Immunotherapy$613,750
R01 · FY2017 · CA · contact PI
Immune Impact on Cancer Chemoresistance$609,903
R01 · FY2017 · CA · contact PI
Immune Regulation in the Microenvironment of Oropharyngeal Cancer$581,720
R01 · FY2017 · CA · contact PI
Effector T Cell Trafficking in Ovarian Cancer$513,972
R01 · FY2017 · CA · contact PI
MDSCs in Ovarian Cancer$498,257
R01 · FY2017 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$206,509
T32 · FY2017 · CA · contact PI
Immune Regulation in the Microenvironment of Oropharyngeal Cancer$581,720
R01 · FY2016 · CA · contact PI
Effector T Cell Trafficking in Ovarian Cancer$513,972
R01 · FY2016 · CA · contact PI
MDSCs in Ovarian Cancer$498,257
R01 · FY2016 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$220,417
T32 · FY2016 · CA · contact PI
Immune Regulation in the Microenvironment of Oropharyngeal Cancer$581,720
R01 · FY2015 · CA · contact PI
Effector T Cell Trafficking in Ovarian Cancer$514,525
R01 · FY2015 · CA · contact PI
MDSCs in Ovarian Cancer$498,257
R01 · FY2015 · CA · contact PI
Memory T Cells in the Tumor Microenvironment$393,042
R01 · FY2015 · CA · contact PI
Hypoxia and Regulatory T cells in Cancer$322,663
R01 · FY2015 · CA · contact PI
Immune Regulation in the Microenvironment of Oropharyngeal Cancer$518,635
R01 · FY2014 · CA · contact PI
Memory T Cells in the Tumor Microenvironment$381,250
R01 · FY2014 · CA · contact PI
Hypoxia and Regulatory T cells in Cancer$312,983
R01 · FY2014 · CA · contact PI
Human Tregs in Ovarian Cancer$210,460
R01 · FY2014 · CA · contact PI
Immune Regulation in the Microenvironment of Oropharyngeal Cancer$534,676
R01 · FY2013 · CA · contact PI
Memory T Cells in the Tumor Microenvironment$369,459
R01 · FY2013 · CA · contact PI
Hypoxia and Regulatory T cells in Cancer$303,303
R01 · FY2013 · CA · contact PI
Human Tregs in Ovarian Cancer$203,951
R01 · FY2013 · CA · contact PI
Memory T Cells in the Tumor Microenvironment$393,042
R01 · FY2012 · CA · contact PI
Hypoxia and Regulatory T cells in Cancer$322,663
R01 · FY2012 · CA · contact PI
Human Tregs in Ovarian Cancer$216,969
R01 · FY2012 · CA · contact PI
Memory T Cells in the Tumor Microenvironment$393,042
R01 · FY2011 · CA · contact PI
Hypoxia and Regulatory T cells in Cancer$321,625
R01 · FY2011 · CA · contact PI
Novel immunosupressive macrophages in human ovarian tumor$280,136
R01 · FY2011 · CA · contact PI
Human Tregs in Ovarian Cancer$216,969
R01 · FY2011 · CA · contact PI
Regulatory T Cells and Tumor Bone Marrow Metastasis$320,588
R01 · FY2010 · CA · contact PI
Novel immunosupressive macrophages in human ovarian tumor$288,800
R01 · FY2010 · CA · contact PI
Human Tregs in Ovarian Cancer$223,679
R01 · FY2010 · CA · contact PI
Regulatory T Cells and Tumor Bone Marrow Metastasis$320,588
R01 · FY2009 · CA · contact PI
Novel immunosupressive macrophages in human ovarian tumor$288,800
R01 · FY2009 · CA · contact PI
Novel immunosupressive macrophages in human ovarian tumor$288,800
R01 · FY2008 · CA · contact PI
Human Tregs in Ovarian Cancer$209,581
R01 · FY2008 · CA · contact PI
Novel immunosupressive macrophages in human ovarian tumor$288,800
R01 · FY2007 · CA · contact PI
Human Tregs in Ovarian Cancer$285,581
R01 · FY2007 · CA · contact PI
Tumor plasmacytoid dendritic cells and tumor immunity$251,461
R01 · FY2007 · CA · contact PI
Human Tregs in Ovarian Cancer$215,840
R01 · FY2006 · CA · contact PI
Tumor environmental CD4+CD25+ T cells$147,700
R21 · FY2006 · CA · contact PI
Tumor plasmacytoid dendritic cells and tumor immunity$127,680
R01 · FY2006 · CA · contact PI
Tumor plasmacytoid dendritic cells and tumor immunity$264,330
R01 · FY2005 · CA
Tumor plasmacytoid dendritic cells and tumor immunity$259,124
R01 · FY2005 · CA
Tumor environmental CD4+CD25+ T cells$147,616
R21 · FY2005 · CA
Tumor environmental CD4+CD25+ T cells$52,859
R21 · FY2005 · CA
Tumor plasmacytoid dendritic cells and tumor immunity$264,330
R01 · FY2004 · CA
Tumor environmental CD4+CD25+ T cells$200,475
R21 · FY2004 · CA
Tumor plasmacytoid dendritic cells and tumor immunity$264,330
R01 · FY2003 · CA